Premium Nahrungsergänzungsmittel | artgerecht

Survodutide: Mechanism, Uses & Clinical Trials

Survodutide is a dual GLP-1/glucagon receptor agonist in clinical development for the treatment of obesity and metabolic dysfunction-associated steatotic liver disease (MASLD).

Regular tips about health Regular tips about health

Things worth knowing about "Survodutide"

Survodutide is a dual GLP-1/glucagon receptor agonist in clinical development for the treatment of obesity and metabolic dysfunction-associated steatotic liver disease (MASLD).

What is Survodutide?

Survodutide (development code BI 456906) is an innovative dual receptor agonist that simultaneously activates both the GLP-1 receptor (glucagon-like peptide-1) and the glucagon receptor. The molecule was co-developed by Boehringer Ingelheim and Zymeworks and is currently being investigated in advanced Phase II and Phase III clinical trials. The primary target indications are obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

Mechanism of Action

Survodutide combines two complementary mechanisms of action within a single molecule:

GLP-1 receptor activation: GLP-1 is an intestinal hormone released after food intake. It stimulates insulin secretion, suppresses appetite, and slows gastric emptying, thereby reducing caloric intake and increasing satiety.
Glucagon receptor activation: Glucagon is a pancreatic hormone that boosts energy metabolism, increases hepatic fat oxidation, and raises overall energy expenditure. The combined activation of both receptors is intended to produce synergistic effects on weight loss and hepatic fat reduction.

This dual approach aims to achieve greater weight reduction and more pronounced liver fat loss compared to what is possible with pure GLP-1 agonists alone.

Indications

Obesity

In Phase II clinical trials, survodutide demonstrated significant body weight reduction in adults with overweight or obesity. Results suggest that the compound may achieve above-average weight loss compared to existing therapies. Phase III studies to confirm these findings are currently ongoing.

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD/MASH)

MASLD, formerly called NAFLD, is a prevalent liver disease closely linked to obesity, type 2 diabetes, and metabolic syndrome. In clinical trials, survodutide showed marked reductions in liver fat content as well as improvements in histological liver parameters in patients with MASH (metabolic dysfunction-associated steatohepatitis). This makes survodutide a promising candidate for a disease that currently has very few approved treatment options.

Dosage and Administration

Survodutide is administered as a subcutaneous injection (under the skin), similar to other GLP-1 receptor agonists. Various doses have been investigated in clinical trials, with doses typically escalated gradually to improve tolerability. The exact dosing recommendation for potential approval has not yet been established, as the drug is still in clinical development.

Side Effects

The side effect profile of survodutide is broadly consistent with that of other incretin-based therapies. The most frequently observed adverse effects in clinical trials include:

Gastrointestinal complaints: Nausea, vomiting, diarrhea, and constipation, particularly at the start of treatment or during dose escalation.
Decreased appetite
Increased heart rate (attributed to the glucagon component)
Potentially elevated liver enzyme levels, which should be monitored regularly.

Serious adverse events are rare, but the glucagon-activating component may theoretically affect blood glucose levels. Patients with certain pre-existing conditions should discuss the use of survodutide with their physician.

Development Status and Approval

At the present time, survodutide is not yet approved and is therefore not commercially available as a medicinal product. Several clinical trials in Phases II and III are underway, and their results will determine whether regulatory approval will be sought. The development is being closely followed by the medical community, given the high unmet need for effective therapies for obesity and MASLD.

References

Boehringer Ingelheim / Zymeworks: Clinical study data for BI 456906 (Survodutide), Phase II results, published on ClinicalTrials.gov (NCT study numbers NCT04964583, NCT05350163).
Romero-Gomez M. et al. - Survodutide for the treatment of metabolic dysfunction-associated steatohepatitis. The Lancet, 2024.
World Health Organization (WHO) - Obesity and overweight. Fact Sheet, 2024. Available at: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.